SCHEMBL4116381

SCHEMBL4116381

CCN(CC)CCN(CCNC(=O)Nc1cccc(C(F)(F)F)c1)C(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 4/20 0.58
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ MAPT P10636 4/20 0.52
▸ HTT P42858 4/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ NPSR1 Q6W5P4 2/20 0.52
▸ TP53 P04637 2/20 0.49
▸ RAB9A P51151 1/20 0.48
▸ LMNA P02545 3/20 0.48
▸ GAA P10253 1/20 0.48
▸ XBP1 P17861 1/20 0.48
▸ PAX8 Q06710 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ BRAF P15056 1/20 0.47
▸ KDR P35968 1/20 0.47
▸ MAPK14 Q16539 1/20 0.47
▸ TNNI3K Q59H18 1/20 0.47
▸ CNR1 P21554 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4107284 0.96 MCHR1 (0.59) MCHR1MEN1KMT2AMAPTHTT
SCHEMBL4115328 0.92 MCHR1 (0.61) MCHR1MEN1KMT2AMAPTHTT
SCHEMBL4118376 0.92 MCHR1 (0.66) MCHR1MEN1KMT2ASMN1; SMN2CNR1
SCHEMBL4119938 0.90 TP53 (0.54) MCHR1MEN1KMT2AMAPTHTT
SCHEMBL4119645 0.87 MCHR1 (0.60) MCHR1MEN1KMT2AMAPTHTT
SCHEMBL4107405 0.87 MCHR1 (0.60) MCHR1MEN1KMT2AMAPTHTT
SCHEMBL4106239 0.86 MCHR1 (0.52) MCHR1MEN1KMT2AHTTSMN1; SMN2
SCHEMBL4114182 0.86 MCHR1 (0.59) MCHR1MEN1KMT2AMAPTHTT
SCHEMBL4107391 0.86 MCHR1 (0.64) MCHR1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL4107568 0.85 MCHR1 (0.58) MCHR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US claimed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP claimed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO claimed
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US disclosed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP disclosed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118330-A1 Diurea derivatives IL2, CASP2, MAVS MCHR1 4128/4885MEN1 4167/4885KMT2A 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback